For research use only. Not for therapeutic Use.
LY3522348（Cat No.:I041092）is an investigational drug developed by Eli Lilly and Company, designed as a selective inhibitor targeting specific pathways involved in immune responses. It has shown potential in treating autoimmune diseases and inflammatory conditions by modulating the activity of certain immune cells. This oral medication is being evaluated for its efficacy and safety in clinical trials, with promising results in reducing inflammation and improving symptoms in patients with conditions like rheumatoid arthritis. LY3522348 represents a novel approach to treating immune-mediated disorders with minimal systemic side effects.
| CAS Number | 2568608-48-8 |
| Synonyms | 2-[4-[2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]pyrazol-1-yl]-1-piperazin-1-ylethanone |
| Molecular Formula | C18H22F3N7O |
| Purity | ≥95% |
| IUPAC Name | 2-[4-[2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]pyrazol-1-yl]-1-piperazin-1-ylethanone |
| InChI | InChI=1S/C18H22F3N7O/c1-12-2-5-28(12)17-24-14(8-15(25-17)18(19,20)21)13-9-23-27(10-13)11-16(29)26-6-3-22-4-7-26/h8-10,12,22H,2-7,11H2,1H3/t12-/m0/s1 |
| InChIKey | HAUDFIFEGDNKJX-LBPRGKRZSA-N |
| SMILES | C[C@H]1CCN1C2=NC(=CC(=N2)C(F)(F)F)C3=CN(N=C3)CC(=O)N4CCNCC4 |
